Header Logo

Connection

MARIA BOTTAZZI to Trypanosoma cruzi

Back to Details
This is a "connection" page, showing publications MARIA BOTTAZZI has written about Trypanosoma cruzi.
MARIA BOTTAZZI
Connection Strength
4.654
Trypanosoma cruzi
  1. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.423
  2. Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response. Vaccine. 2026 Mar 19; 76:128296.
    View in: PubMed
    Score: 0.186
  3. Different responses involving Tfh cells delay parasite-specific antibody production in Trypanosoma cruzi acute experimental models. Front Immunol. 2025; 16:1487317.
    View in: PubMed
    Score: 0.176
  4. Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidate. PLoS Pathog. 2024 12; 20(12):e1012764.
    View in: PubMed
    Score: 0.172
  5. Chagasin from Trypanosoma cruzi as a molecular scaffold to express epitopes of TSA-1 as soluble recombinant chimeras. Protein Expr Purif. 2024 06; 218:106458.
    View in: PubMed
    Score: 0.163
  6. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 11; 17(11):e0011519.
    View in: PubMed
    Score: 0.160
  7. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease. Nat Commun. 2023 10 25; 14(1):6769.
    View in: PubMed
    Score: 0.159
  8. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis. Vaccine. 2023 08 23; 41(37):5400-5411.
    View in: PubMed
    Score: 0.156
  9. Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models. Microbiol Spectr. 2023 06 15; 11(3):e0019923.
    View in: PubMed
    Score: 0.154
  10. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.151
  11. Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2022 11; 16(11):e0010376.
    View in: PubMed
    Score: 0.148
  12. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice. PLoS Negl Trop Dis. 2022 09; 16(9):e0010258.
    View in: PubMed
    Score: 0.147
  13. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.145
  14. Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2021 09; 15(9):e0009689.
    View in: PubMed
    Score: 0.137
  15. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.137
  16. Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. Front Cell Infect Microbiol. 2021; 11:708325.
    View in: PubMed
    Score: 0.137
  17. Alterations to the Cardiac Metabolome Induced by Chronic T. cruzi Infection Relate to the Degree of Cardiac Pathology. ACS Infect Dis. 2021 06 11; 7(6):1638-1649.
    View in: PubMed
    Score: 0.133
  18. Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen,?Trypanosoma cruzi. Front Cell Infect Microbiol. 2021; 11:614665.
    View in: PubMed
    Score: 0.132
  19. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep. 2021 02 05; 11(1):3222.
    View in: PubMed
    Score: 0.131
  20. Mining the Metabolome for New and Innovative Chagas Disease Treatments. Trends Pharmacol Sci. 2021 01; 42(1):1-3.
    View in: PubMed
    Score: 0.130
  21. Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques. Vaccine. 2020 06 15; 38(29):4584-4591.
    View in: PubMed
    Score: 0.125
  22. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.112
  23. Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. Infect Immun. 2018 04; 86(4).
    View in: PubMed
    Score: 0.108
  24. Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. PLoS Negl Trop Dis. 2018 01; 12(1):e0006240.
    View in: PubMed
    Score: 0.107
  25. Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
    View in: PubMed
    Score: 0.102
  26. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.097
  27. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother. 2016 04 02; 12(4):976-87.
    View in: PubMed
    Score: 0.093
  28. Identification and Characterization of the Trypanosoma cruzi B-cell Superantigen Tc24. Am J Trop Med Hyg. 2016 Jan; 94(1):114-121.
    View in: PubMed
    Score: 0.092
  29. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice. Vaccine. 2015 Aug 26; 33(36):4505-12.
    View in: PubMed
    Score: 0.089
  30. Limited antigenic variation in the Trypanosoma cruzi candidate vaccine antigen TSA-1. Parasite Immunol. 2014 Dec; 36(12):708-12.
    View in: PubMed
    Score: 0.086
  31. Trypanosoma cruzi screening in Texas blood donors, 2008-2012. Epidemiol Infect. 2016 Apr; 144(5):1010-3.
    View in: PubMed
    Score: 0.084
  32. An unfolding tragedy of Chagas disease in North America. PLoS Negl Trop Dis. 2013; 7(10):e2300.
    View in: PubMed
    Score: 0.079
  33. A new patient registry for Chagas disease. PLoS Negl Trop Dis. 2020 10; 14(10):e0008418.
    View in: PubMed
    Score: 0.032
  34. TLR4 agonist protects against Trypanosoma cruzi acute lethal infection by decreasing cardiac parasite burdens. Parasite Immunol. 2020 10; 42(10):e12769.
    View in: PubMed
    Score: 0.032
  35. Reproductive Outcomes in Rhesus Macaques (Macaca mulatta) with Naturally-acquired Trypanosoma cruzi Infection. Comp Med. 2020 04 01; 70(2):152-159.
    View in: PubMed
    Score: 0.031
  36. A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2019 05; 13(5):e0007413.
    View in: PubMed
    Score: 0.029
  37. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.029
  38. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Rev Anti Infect Ther. 2019 03; 17(3):145-157.
    View in: PubMed
    Score: 0.029
  39. The BENEFIT Trial: Where Do We Go from Here? PLoS Negl Trop Dis. 2016 Feb; 10(2):e0004343.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.